MYGN - Myriad Genetics, Inc.
NEXT EARNINGS:
Apr 30, 2026
EPS Est: $-0.05
|
Rev Est: $204.3M
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$6.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
35.44%
Market Cap:
412.94M
Volume:
5,211,906
Avg Volume:
968,803
52 Week Range:
3.76-14.73
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
1.89
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
2,700
IPO Date:
1995-10-06
EPS (TTM):
-3.96
P/E Ratio:
-1.57
Revenue (TTM):
824.50M
Total Assets:
706.60M
Total Debt:
209.80M
Cash & Equiv:
149.60M
Rev Growth (5Y):
8.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
-37.7%
ROCE:
N/A
Debt/Equity:
0.57
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-23 | $0.04 | $-0.02 | +300.0% | $209.8M | $208.4M | +0.7% |
| 2025-11-03 | $-0.13 | $-0.01 | -1200.0% | $205.7M | $207.0M | -0.6% |
| 2025-08-05 | $0.05 | $-0.01 | +600.0% | $213.1M | $205.2M | +3.8% |
| 2025-05-06 | $-0.03 | $-0.05 | +40.0% | $195.9M | $211.7M | -7.5% |
| 2025-02-24 | $0.03 | $0.03 | 0.0% | $210.6M | $210.3M | +0.1% |
| 2024-11-07 | $0.06 | $0.02 | +215.8% | $213.3M | $213.6M | -0.1% |
| 2024-08-06 | $0.05 | $0.01 | +509.0% | $211.5M | $204.9M | +3.2% |
| 2024-05-07 | $-0.01 | $-0.11 | +90.9% | $202.2M | $193.5M | +4.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 824.50M | 837.60M | 753.20M | 678.40M | 690.60M | 557.00M | 638.60M | 851.10M | 772.60M | 771.40M | 753.80M | 723.10M |
| Net Income | (365.90M) | (127.30M) | (263.30M) | (112.00M) | (27.20M) | (223.70M) | (199.50M) | 4.60M | 131.00M | 21.80M | 125.30M | 80.20M |
| EPS | -3.96 | -1.41 | -3.18 | -1.39 | -0.35 | -2.99 | -2.69 | 0.06 | 1.89 | 0.32 | 1.79 | 1.12 |
| Total Assets | 706.60M | 1.03B | 1.15B | 1.20B | 1.32B | 1.42B | 1.56B | 1.56B | 1.17B | 1.22B | 880.50M | 766.20M |
| Total Debt | 209.80M | 140.30M | 152.10M | 145.00M | 92.30M | 289.00M | 233.50M | 233.50M | 9.30M | 99.10M | 0 | 0 |
| Cash & Equivalents | 149.60M | 102.40M | 132.10M | 56.90M | 258.40M | 117.00M | 93.20M | 93.20M | 110.90M | 102.40M | 68.50M | 64.10M |
| Operating Cash Flow | 1.80M | (8.70M) | (110.90M) | (106.30M) | 18.60M | (26.90M) | 60.70M | 83.70M | 115.90M | 106.20M | 166.30M | 140.50M |
| Free Cash Flow | 1.80M | (38.40M) | (184.20M) | (151.60M) | 600,000 | (40.10M) | 50.50M | 75.10M | 107.50M | 100.10M | 161.30M | 116.60M |
| FCF per Share | 0.02 | -0.42 | -2.22 | -1.88 | 0.01 | -0.54 | 0.68 | 1.02 | 1.55 | 1.47 | 2.30 | 1.64 |
| Book Value | 368.00M | 701.10M | 783.20M | 885.80M | 967.80M | 881.00M | 1.09B | 1.09B | 964.90M | 778.20M | 748.10M | 662.10M |
| Cash & ST Investments | 149.60M | 102.40M | 140.90M | 114.90M | 339.80M | 150.70M | 136.90M | 136.90M | 180.60M | 150.70M | 159.00M | 144.80M |
| ROC Equity | -0.99 | -0.18 | -0.34 | -0.13 | -0.03 | -0.25 | -0.18 | 0.00 | 0.14 | 0.03 | 0.17 | 0.12 |